Europe Human Papillomavirus Vaccines Market Size, Share, and Growth Forecast 2026 - 2033

The Europe human papillomavirus vaccines market is expected to be valued at US$ 1.5 billion in 2026 and is projected to reach US$ 2.5 billion, growing at a CAGR of 7.3% between 2026 and 2033. Coordinated regional cervical cancer elimination policies are a key factor driving market growth.

The European Commission's Europe's Beating Cancer Plan, alongside the World Health Organization (WHO) Regional Office for Europe's cervical cancer elimination roadmap, has encouraged national immunization committees across Germany, France, and the U.K. to expand school-based vaccination programs. Rising adoption of gender-neutral vaccination and expanding catch-up campaigns for young adults are further supporting sustained regional demand for nonavalent formulations.

Drivers - Coordinated EU Public Health Policy and National Immunization Funding

Harmonized public health policies across the European Union are a key growth driver for the Europe human papillomavirus vaccines market. The European Centre for Disease Prevention and Control (ECDC) monitors HPV vaccination coverage across member states, while the WHO Regional Office for Europe's cervical cancer elimination initiative targets 90% HPV vaccination coverage among girls by age 15 across member states.

National immunization technical advisory groups in Germany (STIKO), France (Haute Autorité de Santé), and the U.K. (JCVI) have progressively expanded publicly funded vaccination programs to include boys, supported by government-funded procurement. This coordinated funding framework, combined with expanding catch-up eligibility through age 26 in several member states, is supporting the integration of HPV vaccination into routine adolescent preventive care and sustaining procurement demand for manufacturers such as Merck & Co., Inc. and GlaxoSmithKline plc (GSK). Public funding also helps reduce financial barriers to vaccination, particularly across lower-income member states.

Rising Burden of HPV-Associated Cancers Reinforcing Preventive Uptake

The burden of HPV-associated cancers across Europe is increasing attention toward vaccination among clinicians and health ministries. The International Agency for Research on Cancer (IARC), headquartered in Lyon, France, attributes more than 90% of cervical cancer cases globally to persistent HPV infection, while the ECDC has reported increasing incidence of oropharyngeal cancer among men across parts of Western Europe.

National cancer registries in Germany, Italy, and Spain continue to document significant HPV-attributable disease across anal, vulvar, and oropharyngeal cancer sites. These epidemiological trends are supporting physician recommendations and public health messaging around gender-neutral vaccination, contributing to increased vaccination demand across pediatric and adult healthcare settings. Screening and vaccination are also increasingly incorporated into broader national cancer prevention strategies.

Restraints - Uneven Vaccination Coverage and Persistent Hesitancy Across Member States

Differences in HPV vaccination coverage across European Union member states continue to constrain uniform market growth. While Nordic countries and the U.K. report adolescent HPV vaccination coverage above 80%, the ECDC identifies lower completion rates in several Southern and Eastern European countries, including parts of Italy, due to differences in regional implementation and parental hesitancy. Uneven uptake, combined with vaccine safety misinformation circulating through social media, is slowing the conversion of eligible populations into fully vaccinated cohorts despite supportive national policies. Several health ministries are therefore increasing targeted provider-led counseling to address information gaps and improve vaccination completion.

Budget Constraints Within National Healthcare Procurement Systems

Centralized public procurement across European healthcare systems creates strict budget considerations during vaccine tendering, increasing pricing pressure and influencing the adoption of higher-priced nonavalent formulations in cost-constrained regions. Reimbursement negotiations between manufacturers and national health authorities in Spain and Italy can extend procurement timelines, while constrained healthcare budgets in select member states limit the simultaneous expansion of catch-up and male vaccination programs. These factors are expected to moderate the near-term pace of market volume growth, particularly across smaller national healthcare systems with limited annual immunization budgets.

Opportunities - Renewed Interest in Single-Dose and Bivalent Regimens for Cost-Efficient Scale-Up

The WHO single-dose HPV vaccination recommendation, designed to support broader vaccination coverage through simplified dosing, is influencing procurement strategies among European public health programs seeking cost-efficient vaccination approaches. This trend is creating opportunities for bivalent HPV vaccines within national immunization programs, particularly in Southern and Eastern European member states seeking to expand population coverage while managing vaccination budgets.

Manufacturers positioning bivalent vaccines for European public procurement, including emerging producers such as Serum Institute of India Pvt. Ltd. and Xiamen Innovax Biotech Co., Ltd., are positioned to address incremental demand as national health authorities evaluate dose-sparing strategies. These approaches are particularly relevant for historically under-vaccinated adolescent populations, including rural communities where multi-visit vaccination schedules present logistical challenges.

Expanding Male Vaccination Coverage and Adult Catch-Up Programs

Growing clinical recognition of HPV's association with anal, penile, and oropharyngeal cancers among men presents an opportunity to expand vaccination coverage across Europe. National advisory bodies, including STIKO in Germany and the JCVI in the U.K., recommend gender-neutral vaccination, while male vaccination initiation rates continue to lag female rates in several member states based on ECDC surveillance data. Expanded catch-up eligibility, targeted school-based outreach, and awareness campaigns from national cancer organizations are expected to support greater male vaccination uptake and narrow the gender coverage gap.

Companies investing in male-focused outreach, physician education, and public-private immunization partnerships are likely to benefit from increasing vaccination demand within this underserved population segment. Growing emphasis on preventive oncology and broader adult immunization programs is expected to further support male catch-up vaccination through the forecast period.

Vaccine Type Insights

Nonavalent (9-valent) HPV vaccines are the leading vaccine type segment, holding around 89% share of the Europe human papillomavirus vaccines market in 2026. Their leading position is supported by broader serotype coverage against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, providing protection against a wide range of HPV-related diseases. National immunization programs in Germany, France, and the U.K. have increasingly shifted procurement toward nonavalent formulations, making Merck & Co., Inc.'s Gardasil 9 the primary vaccine used across routine public immunization programs. This procurement preference has limited the role of legacy bivalent and quadrivalent formulations in routine adolescent vaccination.

Bivalent HPV vaccines represent the fastest-growing vaccine type, driven by increasing interest in cost-efficient vaccination strategies and simplified dosing approaches aligned with WHO single-dose guidance. Their lower serotype coverage compared with nonavalent vaccines is balanced by potential procurement and coverage advantages in programs focused on expanding vaccination access and improving population-level immunization rates.

Application Insights

Cervical cancer remains the leading application, accounting for an estimated 44% share of the Europe human papillomavirus vaccines market in 2026. This leading position reflects cervical cancer's role as the primary indication associated with HPV vaccination, supported by extensive epidemiological evidence and established screening and vaccination programs. National cervical cancer elimination strategies across Germany, France, Italy, and Spain continue to emphasize HPV vaccination as a key preventive measure, while growing awareness of genital warts and other HPV-associated cancers is expanding the broader clinical relevance of vaccination across the region.

Germany Human Papillomavirus Vaccines Market Insights

Germany is expected to lead the Europe human papillomavirus vaccines market, accounting for around 30% share in 2026. The country's leading position is supported by STIKO-recommended gender-neutral vaccination, statutory health insurance reimbursement, and established primary-care and pediatric healthcare networks. Routine adolescent vaccination remains a major source of vaccine demand, while catch-up vaccination provides an additional source of doses among older adolescents and young adults. Increasing awareness of HPV-associated cancers and preventive healthcare is supporting broader vaccine acceptance. Continued integration of vaccination through primary-care services, pharmacies, and public health initiatives is expected to sustain procurement demand through 2033.

U.K. Human Papillomavirus Vaccines Market Insights

The U.K. is expected to hold a significant share of the Europe human papillomavirus vaccines market in 2026, supported by the National Health Service (NHS) school-based vaccination program and JCVI-endorsed gender-neutral vaccination recommendations. High historical vaccination coverage among adolescents provides a stable foundation for continued demand, while publicly funded immunization supports broad access. Catch-up vaccination delivered through general practitioners and community healthcare services provides an additional demand source among eligible individuals who missed routine vaccination. Increasing awareness of HPV-related cancers and efforts to improve uptake among underserved populations are supporting market development. Established procurement mechanisms across England, Scotland, Wales, and Northern Ireland are expected to sustain vaccine demand through 2033.

France Human Papillomavirus Vaccines Market Insights

France is projected to be the fastest-growing national market through 2033, driven by government efforts to increase HPV vaccination coverage and reduce disparities in preventive healthcare. Expanded gender-neutral vaccination recommendations have increased eligibility among adolescents, while school-based vaccination initiatives are improving access and convenience. Pharmacist involvement in vaccine administration is also expanding vaccination access beyond traditional physician settings. National awareness campaigns highlighting the relationship between HPV infection and multiple cancers are supporting greater acceptance among adolescents and parents. Continued public funding, catch-up initiatives, and targeted outreach to populations with historically lower vaccination rates are expected to support higher vaccination volumes and strengthen France's contribution to the European HPV vaccine market.

Italy Human Papillomavirus Vaccines Market Insights

Italy is anticipated to hold a considerable share of the market in 2026, supported by nationally guided immunization policies and regionally administered vaccination programs. The National Immunization Prevention Plan provides the broader framework for HPV vaccination, while regional health authorities manage program implementation and delivery. Efforts to improve vaccination coverage across regions remain an important market driver, particularly in areas where uptake has historically lagged national targets. Expansion of free or publicly funded vaccination for eligible adolescents and young adults is supporting broader access. Increasing awareness of HPV-related cancers and preventive healthcare is expected to encourage additional vaccine uptake and gradual dose-volume growth throughout the forecast period.

Spain Human Papillomavirus Vaccines Market Insights

Spain is projected to hold a notable share of the Europe human papillomavirus vaccines market in 2026, supported by the National Health System and inclusion of HPV vaccination within the national immunization schedule. The expansion of routine vaccination to boys has broadened the eligible population and strengthened the gender-neutral approach to HPV prevention. Regional health authorities play an important role in program implementation, while publicly funded vaccination supports accessibility among adolescents. Increasing awareness of HPV-associated cervical and other cancers is encouraging greater acceptance among parents and young adults. Continued efforts to improve vaccination coverage, strengthen school- and healthcare-based delivery, and reach under-vaccinated populations are expected to support incremental market growth through 2033.

The Europe human papillomavirus vaccines market is highly consolidated, with Merck & Co., Inc. and GlaxoSmithKline plc (GSK) together accounting for the overwhelming majority of regional supply through Gardasil 9 and Cervarix, respectively. Competitive strategy centers on national tender participation, long-term supply agreements with health ministries, and continued clinical evidence generation supporting broader age-range and gender-neutral indications.

Emerging manufacturers, including Xiamen Innovax Biotech Co., Ltd., Walvax Biotechnology Co., Ltd., and Serum Institute of India Pvt. Ltd., are pursuing WHO prequalification and European regulatory engagement, while established players differentiate through pipeline investment in next-generation multivalent and mRNA-based candidate vaccines. Emerging business models increasingly favor bundled immunization service agreements with national health systems, combining vaccine supply with patient-reminder technology and outcomes tracking to strengthen completion rates.

Key Industry Developments

• In March 2026, Merck announced that it presented new clinical data at the EUROGIN International Multidisciplinary HPV Congress 2026, reinforcing the long-term efficacy, durability, and safety profile of its GARDASIL 9 and GARDASIL human papillomavirus (HPV) vaccines. The findings highlighted sustained protection against HPV-related infections and precancerous lesions over extended follow-up periods, further supporting the vaccines' role in preventing cervical and other HPV-associated cancers.